5 Best Compounding Pharmacies for Semaglutide & Tirzepatide in 2026
We independently vetted dozens of compounding pharmacies on accreditation, sterility testing, pricing, cold-chain logistics, and patient safety documentation. These 5 passed every check—and one offers both semaglutide and tirzepatide at $146/month flat.
How Compounding Pharmacies Work
Compounding pharmacies create customized medications by combining pharmaceutical-grade raw ingredients into finished dosage forms—in this case, injectable semaglutide and tirzepatide solutions. This is legal and has been practiced for over a century. What makes the current GLP-1 compounding landscape unique is the FDA shortage designation.
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may produce copies of commercially available drugs when those drugs are on the FDA's official shortage list. Both semaglutide and tirzepatide have maintained shortage designations since 2022-2023, enabling legal compounding by licensed pharmacies. The active pharmaceutical ingredient (API) is sourced from FDA-inspected raw material suppliers and compounded into the same concentration and injection format as brand-name products.
The critical variable is pharmacy quality. A well-run 503A pharmacy with PCAB accreditation, rigorous sterility protocols, and third-party potency testing produces medication that is functionally equivalent to brand-name product. A poorly run pharmacy cutting corners on sterility, potency testing, or storage conditions introduces real patient safety risks including under-dosing, contamination, and degraded medication that has lost its therapeutic potency. This guide helps you identify the difference between pharmacies that prioritize patient safety and those that prioritize profit margins.
The Rankings
Telehealth FX partners with PCAB-accredited 503A compounding pharmacies that maintain full sterility testing protocols, beyond-use dating documentation, and third-party potency verification for every batch. Both compounded semaglutide and tirzepatide are available at the same flat $146/month—the lowest verified price for pharmacy-compounded GLP-1 medications from accredited facilities. Cold-chain shipping is standard on every order. Physician consultation, dose titration management, and follow-up are included at no additional cost. No contracts, no enrollment fees, cancel anytime.
Get Started at Telehealth FX →Hallandale is one of the most established 503B outsourcing facilities in the compounded GLP-1 space. As a 503B facility, it operates under direct FDA oversight with current Good Manufacturing Practice (cGMP) requirements, regular federal inspections, and mandatory batch-level testing. The manufacturing standards are comparable to pharmaceutical manufacturers. The trade-off is pricing—Hallandale's compounded semaglutide is available through various telehealth providers at $199-$299/month, significantly higher than 503A alternatives. Patients who prioritize maximum manufacturing oversight may find the premium worthwhile.
Empower Pharmacy operates both 503A and 503B divisions, giving it flexibility to compound both individual prescriptions and larger batches. PCAB-accredited with publicly available Certificates of Analysis (CoA) for potency and sterility testing. Empower has become one of the largest compounding pharmacies in the GLP-1 space, partnering with multiple telehealth platforms. Their transparency around testing documentation sets an industry standard. Pricing through partner telehealth platforms ranges from $175-$249/month depending on the provider's markup.
Olympia Pharmaceuticals is an FDA-registered 503B outsourcing facility specializing in injectable compounded medications including semaglutide and tirzepatide. Their cGMP-compliant facility undergoes regular FDA inspections with publicly available inspection reports. Olympia supplies several mid-tier telehealth platforms and maintains consistent quality across their product line. Pricing through telehealth partners ranges from $189-$269/month. Their sterility testing and endotoxin protocols meet USP 797 and USP 800 standards.
Revive Rx is a 503A compounding pharmacy with multi-state licensure and USP 797 compliance for sterile compounding. They specialize in injectable peptides and hormones, making GLP-1 medications a core competency rather than an afterthought. Certificates of Analysis are available upon request for any batch. Their pricing through partner telehealth platforms starts at $165/month, making them competitive on cost while maintaining quality standards. Slightly less established than Empower or Hallandale but growing rapidly.
The Verification Checklist
Before trusting any compounding pharmacy with your GLP-1 medication, verify these credentials independently:
- State Board of Pharmacy License: Search your state's BOP website for the pharmacy name. Every legitimate pharmacy will appear in the state database.
- FDA Registration (503B only): Search the FDA's Registered Outsourcing Facilities database at fda.gov. 503B facilities must be listed.
- PCAB Accreditation (optional but valuable): The Pharmacy Compounding Accreditation Board provides voluntary quality accreditation. Check pcab.org.
- USP 797/800 Compliance: Ask the pharmacy if they follow USP 797 (sterile compounding) and USP 800 (hazardous drug handling) standards.
- Certificate of Analysis (CoA): Request a CoA for your specific batch. It should show potency testing results confirming the correct concentration of semaglutide.
- Beyond-Use Dating (BUD): Compounded medications have expiration dates. Your vial should include a clearly labeled BUD, typically 30-90 days from compounding.
503A vs. 503B: Which Is Better?
| Feature | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Oversight | State Board of Pharmacy | FDA (federal) |
| Inspections | State-level, periodic | FDA, regular |
| Batch size | Individual prescriptions | Large batches |
| cGMP required | No (USP 797 voluntary) | Yes (mandatory) |
| Rx required | Yes (patient-specific) | No (anticipatory) |
| Cost to patient | Lower ($146-$199/mo) | Higher ($199-$299/mo) |
| PCAB accreditation | Voluntary | N/A (FDA-registered) |
Our recommendation: For most patients, a PCAB-accredited 503A pharmacy offers the optimal balance of quality assurance and affordability. The regulatory difference between a well-run 503A and a 503B is meaningful on paper but modest in practice—both produce sterile injectable medications using pharmaceutical-grade APIs from inspected suppliers. Patients with specific concerns about manufacturing oversight may prefer 503B facilities and should expect to pay a $50-$100/month premium for that preference.
What Happens If the Shortage Ends?
The legal basis for compounding semaglutide is the FDA shortage designation. If Novo Nordisk resolves supply constraints and the FDA removes semaglutide from the shortage list, 503A pharmacies would need to stop compounding it within a defined wind-down period. 503B outsourcing facilities may have slightly different regulatory timelines based on their framework and existing inventory.
For patients, this means compounded semaglutide should be viewed as a currently legal and safe option—but not necessarily a permanent one. Discuss contingency plans with your prescribing physician, including potential transition to brand-name medications through insurance coverage, manufacturer savings programs, or alternative GLP-1 medications that may remain on shortage lists independently. As of May 2026, industry analysts project the semaglutide shortage will persist through at least late 2026 based on continued demand-supply gaps, with global prescriptions having grown over 300% since 2022 while manufacturing capacity has expanded at a slower pace.
Sterility Testing: What to Look For
Sterility is the single most important quality metric for any injectable medication. Contaminated injectables can cause serious infections, sepsis, and even death. Legitimate compounding pharmacies follow USP 797 standards for sterile compounding, which require:
- ISO-classified cleanrooms: Compounding occurs in ISO Class 5 (or better) laminar airflow environments within ISO Class 7 buffer rooms
- Environmental monitoring: Regular air and surface sampling for microbial contamination
- Personnel training: Compounding technicians must pass annual aseptic technique validation (media fill testing)
- End-product testing: Sterility testing and bacterial endotoxin testing on finished products
- Potency verification: HPLC or equivalent analytical testing to confirm active ingredient concentration matches the labeled dose
When requesting a Certificate of Analysis, look for sterility test results (should show "no growth"), endotoxin levels (should be below USP limits), and potency results (should be 90-110% of labeled concentration). Any pharmacy that cannot or will not provide this documentation should be avoided entirely.
API Sourcing: Where the Raw Ingredient Comes From
The Active Pharmaceutical Ingredient (API)—the raw semaglutide powder that compounding pharmacies formulate into injectable solutions—must come from FDA-inspected suppliers. Legitimate API suppliers hold Drug Master Files (DMFs) with the FDA and undergo regular inspections for manufacturing quality.
The global semaglutide API market is dominated by a small number of manufacturers, primarily in China and India, with some European and American suppliers entering the market. Quality variation between API suppliers is real—some produce pharmaceutical-grade material with 99%+ purity, while others cut corners with lower-purity material that may contain degradation products or impurities.
Patients cannot verify API sourcing directly, but they can ask their compounding pharmacy two important questions: "Does your API supplier hold an FDA Drug Master File?" and "Can you provide a Certificate of Analysis for the raw material showing purity testing results?" A pharmacy that sources exclusively from DMF-holding suppliers and performs incoming raw material identity and potency testing on every shipment is operating at the highest standard available in the compounding space. This level of quality assurance ensures the semaglutide powder that enters the compounding process is pharmaceutical-grade and free from contamination or degradation.
Storage and Handling: Protecting Your Medication at Home
Compounded semaglutide is a protein-based injectable that degrades when exposed to heat, light, or agitation. Proper storage is essential for maintaining medication potency throughout its beyond-use dating period:
- Refrigeration (36-46°F / 2-8°C): Store unopened vials in the refrigerator, not the freezer. Freezing can denature the protein and render the medication ineffective.
- Light protection: Keep vials in their original packaging or a dark container. Prolonged light exposure degrades semaglutide.
- Room temperature window: Once in use, most compounded semaglutide can be stored at room temperature (up to 77°F) for 28-30 days. Check your pharmacy's specific BUD labeling.
- Never shake: Semaglutide is a protein. Vigorous shaking can cause aggregation and reduce potency. Gently roll the vial if mixing is needed.
- Inspect before injecting: The solution should be clear and colorless. Discard any vial that appears cloudy, discolored, or contains visible particles.
The True Cost Breakdown
When comparing compounding pharmacy prices, look beyond the headline monthly cost. Some providers bundle everything; others charge separately for components that add up quickly:
| Cost Component | Telehealth FX | Industry Average |
|---|---|---|
| Medication (monthly) | $146 | $199-$299 |
| Physician consultation | Included | $0-$99 |
| Enrollment/activation fee | $0 | $0-$99 |
| Shipping | Included | $0-$15 |
| Syringes/supplies | Included | $0-$25 |
| Cancellation fee | $0 | $0-$99 |
| True annual cost | $1,752 | $2,388-$4,788 |
Access Verified Compounded GLP-1 Medications
Semaglutide or tirzepatide from PCAB-accredited pharmacies. $146/month flat. No contracts.
Get Started at Telehealth FX →Frequently Asked Questions
A 503A pharmacy is a traditional compounding pharmacy licensed by state boards of pharmacy that produces customized medications in response to individual patient prescriptions. They operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which exempts them from FDA new drug approval requirements when compounding for identified individual patients. Quality-focused 503A pharmacies voluntarily pursue PCAB accreditation, which requires documented sterility protocols, personnel training, environmental monitoring, and quality assurance programs. The majority of compounded semaglutide in the telehealth market comes from 503A pharmacies, which offer the best balance of quality assurance and patient affordability.
When produced by a properly licensed compounding pharmacy with appropriate potency testing, compounded semaglutide contains the same active pharmaceutical ingredient at the same concentration as brand-name Ozempic. The clinical effects should be equivalent at equivalent doses—the molecule is identical. The key variable is pharmacy quality: a pharmacy performing HPLC potency testing that confirms 90-110% of labeled concentration will produce medication performing identically to brand-name product. This is why verifying your pharmacy's testing protocols and requesting Certificates of Analysis matters more than whether the label says "Ozempic" or "compounded semaglutide."
Verify three independent credentials: (1) State Board of Pharmacy license—every state maintains a searchable online database of licensed pharmacies; the pharmacy must appear with an active, unrestricted license. (2) FDA registration for 503B facilities—search the FDA's Registered Outsourcing Facilities database at fda.gov. (3) PCAB accreditation for 503A facilities—check pcab.org for voluntary quality certification. Additionally, request a Certificate of Analysis (CoA) for your specific medication batch showing sterility testing results ("no growth"), endotoxin levels (below USP limits), and potency verification (90-110% of label claim).
503A pharmacies compound individual patient prescriptions under state board oversight, while 503B outsourcing facilities produce larger batches under direct FDA oversight with mandatory current Good Manufacturing Practice (cGMP) requirements and regular federal inspections. Both can legally compound semaglutide during the FDA shortage. 503B facilities undergo more rigorous manufacturing oversight comparable to pharmaceutical manufacturers. However, PCAB-accredited 503A pharmacies also maintain rigorous quality standards. The practical difference for patients is primarily cost: 503B-sourced medications typically cost $50-$100 more per month due to higher operating costs.
Yes. Tirzepatide (brand names Mounjaro and Zepbound) has also maintained an FDA shortage designation, enabling legal compounding by licensed pharmacies. Not all compounding pharmacies offer both medications—some specialize in semaglutide only. Through Telehealth FX, both compounded semaglutide and compounded tirzepatide are available at the same flat rate of $146/month from PCAB-accredited pharmacy partners. Most competitors charge a significant tirzepatide premium ($249-$399/month), making Telehealth FX's flat pricing structure unusually advantageous for patients who prefer tirzepatide.
Most compounded semaglutide vials carry a beyond-use date (BUD) of 28-30 days once punctured, when stored at controlled room temperature (up to 77°F/25°C). Unopened vials stored under refrigeration (36-46°F/2-8°C) typically have a BUD of 60-90 days from the compounding date. Always check the specific BUD label on your vial—this date is determined by the compounding pharmacy's stability testing data and may vary between pharmacies. Never use medication past its BUD, as potency degradation and potential sterility compromise increase beyond that window.